Your browser doesn't support javascript.
loading
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko, Marina; Stamp, Elaine; Stocken, Deborah D; Husain, Akhtar; Zangarini, Monique; Cranston, Amy; Stones, Robert; Sinclair, Naomi; Hodgson, Kirsty; Bowett, Susan A; Roblin, David; Traversa, Silvio; Plummer, Ruth; Veal, Gareth; Langtry, James A A; Ashworth, Alan; Burn, John; Rajan, Neil.
Afiliação
  • Danilenko M; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Stamp E; Biostatistics Research Group, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Stocken DD; Biostatistics Research Group, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Husain A; Department of Dermatology, Royal Victoria Infirmary, Newcastle, United Kingdom.
  • Zangarini M; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Cranston A; Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Stones R; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Sinclair N; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Hodgson K; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Bowett SA; Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Roblin D; The Francis Crick Institute, London, United Kingdom.
  • Traversa S; Sienna Biopharmaceuticals, Inc, Colleretto Giacosa, Italy.
  • Plummer R; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Veal G; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Langtry JAA; Department of Dermatology, Royal Victoria Infirmary, Newcastle, United Kingdom.
  • Ashworth A; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco.
  • Burn J; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Rajan N; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
JAMA Dermatol ; 154(8): 913-921, 2018 08 01.
Article em En | MEDLINE | ID: mdl-29955768
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma Adenoide Cístico / Inibidores de Proteínas Quinases / Enzima Desubiquitinante CYLD / Compostos Heterocíclicos de 4 ou mais Anéis Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: JAMA Dermatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma Adenoide Cístico / Inibidores de Proteínas Quinases / Enzima Desubiquitinante CYLD / Compostos Heterocíclicos de 4 ou mais Anéis Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: JAMA Dermatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido